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Abstract
Background: Few studies have focused to determine the peculiarities of the course
of pregnancy and pregnancy outcomes after treatment in women with idiopathic
hyperprolactinemia.
Objective: To determine the peculiarities of the course of pregnancy and pregnancy
outcomes in women treated for idiopathic hyperprolactinemia, with history of infertility
and/or recurrent pregnancy loss.
Materials and Methods: A non-randomized controlled study was conducted at the
Center for Reproductive Medicine “Universe” and Medical Clinic “Medhealth” during
2016-2018, involving 96 womenwith idiopathic hyperprolactinemia, aged 20-44 yr with
infertility and/or a history of recurrent pregnancy loss. Prolactin (PRL), follicle-stimulating
hormone, luteinizing hormone, estradiol (E2), free testosterone, and progesteronewere
studied in blood serum using immunoassay analysis method. Before the occurrence of
pregnancy, hyperprolactinemia was treated with bromocriptine. Dydrogesterone was
used to support the luteal phase.
Results: PRL levels decreased significantly and normalized within two-five months,
regular menstrual cycle was restored in two-four months, ovulation was restored in
three-seven months, and pregnancy was achieved in three-fourteen months. E2 and
progesterone levels increased significantly (p<0.001). Prior to the treatment, significant
negative correlation between PRL and E2 (r = -0.386, p = 0.007), PRL and progesterone
(r = -0.420, p = 0.003) was detected. Threatened early abortion prevailed among
pregnancy complications. Pregnancy loss in the first trimester was recorded in 3.12%
of cases.
Conclusion: Pregnancy outcomes in women with idiopathic hyperprolactinemia
are improved by prolonged and continuous treatment with bromocriptine before
pregnancy and administration of dydrogesterone in support of the luteal insufficiency.
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1. Introduction
Prolactin (PRL) is anterior pituitary hormone,
which significantly influences woman’s
reproductive function (1). In cases of abnormal
increase of blood PRL levels, often an ovulation
disorder, luteal phase deficiency, and chronic
anovulation are present that lead to fertility
disorder (2, 3). Moreover, the prevalence of
hyperprolactinemia in women with reproductive
disorders varies between 9 and 17% (4).
Besides infertility, recurrent pregnancy loss (RPL)
is also a significant problem, which ranges from
2-5% among the couples (5). Endocrine factors are
among important causes of RPL, which also include
hyperprolactinemia (6), though its role in RPL is
not completely specified. One of the mechanisms
of negative impact of hyperprolactinemia on
reproductive function is considered to be a luteal
phase deficiency developed on its background
(7). Luteal phase deficiency is considered to
be a condition of decreased progesterone
secretion, which is essential for both the secretory
transformation of endometrium and normal embryo
implantation and growth (8). There are three types
of hyperprolactinemia: mild hyperprolactinemia,
where PRL level varies from 25-50 ng/ml, moderate
hyperprolactinemia, where PRL level is between
50 and 100 ng/ml, and higher PRL levels > 100
ng/ml.
Besides, in about 40% of moderate
hyperprolactinemia, the cause of PRL
hypersecretion cannot be determined. In
such cases, it is qualified as idiopathic
hyperprolactinemia (9-11). Medication treatment
with dopamine agonists is considered as a first-
line treatment for idiopathic hyperprolactinemia.
Currently, the three most widely used medications
in this group are bromocriptine (non-selective
agonist), cabergoline (selective agonist), and
quinagolide (selective agonist). They restore
ovulation and fertility (12). Bromocriptine is
preferred drug among women who want to
give birth. It improves pregnancy outcomes
in women with history of RPL and idiopathic
hyperprolactinemia (13). Although bromocriptine
is considered as safe at early pregnancy stages,
its safety for the whole term of pregnancy is not
yet determined (2). Treatment with bromocriptine
has good outcomes; however, in 75% of cases the
PRL levels increase again after the discontinuation
of treatment (14). It is important for infertility to
maintain low PRL levels from 10-12 months (2).
To date there are very few studies (2, 6, 12, 13)
focused on determining the peculiarities of the
course of pregnancy and pregnancy outcomes
after treatment in women with hyperprolactinemia.
There are no sufficient evidences on the
effectiveness of dopamine agonists in relation
to improved pregnancy outcomes in women
with idiopathic hyperprolactinemia and RPL
(12). It is important to conduct research in this
direction. Therefore, the objective of our study
is to determine the peculiarities of the course of
pregnancy and pregnancy outcomes in women
treated for idiopathic hyperprolactinemia, with
history of infertility and/or RPL.
2. Materials and Methods
A non-randomized controlled study was
conducted at the Center for ReproductiveMedicine
“Universe” and Medical Clinic “Medhealth”
between September 2016 and October 2018
and included 96 women aged 20-44 yr (average
age 29.94 ± 4.59 yr), diagnosed with infertility
and/or two or more pregnancy loss before their
inclusion in the study, and those who had mild and
moderate increase in PRL level (39.0 ng/ml - 68.0
ng/ml; Average 49.46 ± 8.77). The inclusion criteria
of the study were women with infertility and/or RPL
with idiopathic hyperprolactinemia, who had not
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received treatment for six months prior to inclusion
in the study. However, other etiological factors
(such as anatomical, genetic, immunological,
infectious, and other endocrinological factors) of
infertility and/or RPL were considered as the criteria
for non-inclusion in the study. Additionally, those
with hyperprolactinemia due to organic damages,
polycystic ovary syndrome and congenital adrenal
hyperplasia, primary hypothyroidism, or due to
pharmacological medications were also excluded.
Prior to inclusion in the study, all women
were tested on thyroid-stimulating hormone
and free thyroxine levels in blood serum and
underwent ultrasound examination of thyroid
gland. Based on the results of these studies,
hyperprolactinemia developed due to primary
hypothyroidism was excluded. PCOS, as one
of the most prevailed mild and moderate
causes of hyperprolactinemia, was excluded
based on the Rotterdam 2003 Consensus
Diagnostic Criteria for PCOS. Congenital adrenal
hyperplasia was excluded on the basis of hormonal
investigation of 17-hydroxyprogesterone and
dehydroepiandrosterone sulfate. Organic causes
of hyperprolactinemia were excluded with the
study of hypothalamic-pituitary area with the use
of magnetic resonance imaging with contrast
agent.
Women involved in the study were divided into
three groups: group (I) 63 women with primary
infertility; Group (II) 15 women with RPL; and
Group (III) 18 women with secondary infertility.
Group III was further divided into subgroups:
subgroup (A): 7 women with the history of
physiological delivery and subgroup (B): 11 women
with the history of one spontaneous abortion.
Archival material were considered for control-
medical records of 78 women with idiopathic
hyperprolactinemia, who were not treated with
bromocriptine continuously before pregnancy,
stopped taking it immediately as the ovulation
was restored, and did not receive dydrogesterone
neither before nor during pregnancy. During
the study of the history, attention was focused
on peculiarities of menstrual and reproductive
functions. Among the objective data, we
focused on body mass index, galactorrhea,
and dermatopathies (acne, seborrhea, and
hirsutism). All women underwent gynecological
examinations.
Using the immunoassay analysis method (ELISA)
(with the use of Rayto Rt-2100 C Microplate Rider),
the following hormones in the blood serum
were studied: before starting the treatment, the
serum PRL levels were determined twice, on
the 2nd and 3rd days of menstrual cycle: PRL
(initially once a month before the restoration
of normal levels and then once every three
months), follicle-stimulating hormone (FSH),
luteinizing hormone (LH), estradiol (E2), free
testosterone (FT) (initially before treatment and
after PRL levels were normalized), progesterone
level was determined on the 22nd and 23rd
days of cycle (initially before treatment and
after PRL levels were normalized). Prior to
the treatment, in cases of amenorrhea and
oligomenorrhea, hormonal study was conducted
on the days mentioned earlier, following the
menstrual induction. With the use of study device
(Voluson E8) ultrasound examination of small
pelvic cavity organs was performed. Ovulation
was identified with ultrasound examination
through follicle monitoring and determination
of progesterone on the 22nd and 23rd days of
cycle.
Further, women included in the study were
treated with bromocriptine continuously until
the occurrence of pregnancy. Treatment was
started with 1.25 mg daily. Dose was increased
gradually by 1.25 mg every week, until PRL
reached normal levels (to a median of 5.0-7.5
mg/day in two intakes). In order to maintain
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long-term normal PRL levels, bromocriptine was
prescribed in minimal doses (1.25 mg/day in
two intakes) for three menstrual cycles after
restoration of ovulation against the background
of barrier contraception. In order to support
luteal phase, 10 mg dydrogesterone was
prescribed for peroral administration for at
least three menstrual cycles from 14th through
25th day. After the discontinuation of barrier
contraception treatment was continued with
both bromocriptine and dydrogesterone in the
same doses until the occurrence of pregnancy.
For the prevention of luteal deficiency, women
were given dydrogesterone 10 mg daily during
the first trimester of pregnancy. Women with
the history of RPL, dydrogesterone 10 mg
was given twice a day until the 20th week
of pregnancy with gradual dose decrease. In
cases of threatened abortion, they were given
a single dose (40 mg) of dydrogesterone,
followed by 10 mg every 8 hr until symptoms
disappeared. All pregnancy complications
and pregnancy outcomes were accurately
recorded.
2.1. Ethical consideration
The study was approved by the Ethics
Committee of the Center for Reproductive
Medicine “Universe”, Tbilisi, Georgia (No3/2016).
Written informed consent to participate in the
study were obtained from all patients.
2.2. Statistical analysis
While the continuous variables are expressed
as Mean ± SD, the categorical variables are
expressed as frequencies and percentages.
Paired Samples t test was used to compare the
continuous variables, and a correlation analysis
between continuous variables of PRL and other
hormones (FSH, LH, FT, E2, and progesterone)
was performed using the Pearson’s correlation
test. All statistical analyses were performed
using the Statistical Package for the Social
Sciences, version 22.0, SPSS Inc., Chicago, Illinois,
USA.
3. Results
About 78.12% (n = 75) of the women studied
had a history of timely menarche, 21.87% (n = 21),
while delayed menarche and premature menarche
was not observed in any of the cases; 73.96%
(n = 71) had oligomenorrhea, 4.17% (n = 4)
oligomenorrhea, and 14.58% (n = 14) secondary
amenorrhea. While only 7.29% (n = 7) had regular
menstrual cycle, 71.43% (n = 5) had anovulation
and 28.57% (n = 2) had luteal phase deficiency.
Besides, galactorrhea occurred in 30.21% (n = 29).
The body mass index was found within the
normal range (18.5-24.0) in 91.67% (n = 88),
while 8.33% (n = 8) were overweight (25.1-
27.3). Acne was detected in 16.67% (n = 16),
of which 81.25% (n = 13) had mild and 18.75%
(n = 3) moderate acne. Hirsutism was not detected
in any case. The duration of infertility among
women involved in the study made on average
2.55 ± 0.78 years (1.5-4.0). Normal PRL level
was restored in an average of 3.78 ± 1.58
months (2.0-5.0) after the onset of treatment.
Menstrual cycle was regulated in an average
of 3.08 ± 0.79 months (2.0-4.0). Ovulation was
restored in an average of 5.85 ± 1.60 months
(3.0-7.0). Pregnancy was achieved in an average
of 6.57 ± 2.15 months (5.0-14.0). Continuous
treatment with bromocriptine for achievement of
pregnancy took an average of 6.89 ± 2.18 months
(3.0-14.0).
Treatment resulted in significant decrease
in PRL levels and normalization of its
concentration. E2 and progesterone levels
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increased significantly (p < 0.001). While the
FT levels decreased significantly (p < 0.001), it
was within the normal range before and after
treatment. FSH and LH levels were within the
normal range before treatment and did not
change significantly after the treatment (Table
I).
Correlations between PRL and other hormones
were detected. Before treatment, FSH, LH, E2, and
progesterone showed reliable negative correlation
with PRL (Table II).
Among the studied women, threatened early
abortion prevailed among the complications of
pregnancy - 11.45% (n = 11). Its highest rate was
recorded in women with RPL and reached 20%
(n = 3). While among women with secondary
infertility and a history of one spontaneous
abortion, threatened abortion was observed in
18.2% (n = 2), it was observed in 9.5% (n = 6)
of the women with primary infertility. In women
with secondary infertility with the history of
physiological delivery, no case of threatened
early abortion was detected. Threatened preterm
labor was recorded in 4.17% (n = 4) of women
involved in the study and all these occurred
in the group of women with primary infertility
(6.3%) on week 25-28 of pregnancy. Placental
insufficiency occurred in 2.08% (n = 2) and both
cases were recorded in the group of women with
primary infertility (3.17%). Preeclampsia occurred
in 2.08% (n = 2). Both cases occurred in the
group of women with primary infertility and
made up for 3.17%. In both cases, pregnancy
was carried to full term and ended in vaginal
delivery. Pregnancy loss occurred in 3.12% (n = 3).
All the three cases were recorded in group I:
two in the fifth week and one in the seventh
week of pregnancy. In all other cases, pregnancy
ended in a live healthy newborn. About 85.42%
(n = 82) of women involved in the study had a
vaginal delivery. Cesarean section was performed
in 11.46% (n = 11). Cesarean delivery mainly
prevailed in group I and the reasons for cesarean
section were: abnormal fetal position in four
cases, narrow pelvic outlet in four cases, in pelvic
varicose veins in one case, and myopia in two
cases.
Pregnancy loss rate was significantly low
in study group than in the control group. All
cases of pregnancy loss in both the study
and control groups were reported in the first
trimester of pregnancy. Timely delivery rate
was significantly higher in the study group
than in the control group and preterm labor
was reported in the control group only (Table
III).
Table I. Mean hormone levels before and during treatment in women with idiopathic hyperprolactinemia (n = 96)
Hormones Before treatment (initial stage) During treatment (after normalizing prolactin level) T test P-value
PRL 49.46 ± 8.77 12.95 ± 2.66 38.29 <0.0001
FSH 6.35 ± 2.63 6.85 ± 1.37 -1.73 0.0878
LH 6.57 ± 3.37 6.51 ± 0.89 0.17 0.8617
E2 13.59 ± 6.19 71.23 ± 12.06 -45.69 <0.0001
FT 0.96 ± 0.53 0.70 ± 0.42 4.04 0.0001
Progesterone 3.06 ± 1.17 17.36 ± 2.96 -44.96 <0.0001
Data presented as Mean ± SD; Continuous variables were compared using Student t test
PRL: Prolactin; FSH: Follicle-stimulating hormone; LH: Luteinizing hormone; E2: Estradiol; FT: Free testosterone
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Table II. Correlations between prolactin and other hormones in women with idiopathic hyperprolactinemia with the history of

















Correlation analysis between categorical variables was performed by Spearman’s correlation analyses, p-value < 0.05 was
considered as statistically significant, **p < 0.01
PRL: Prolactin; FSH: Follicle-stimulating hormone; LH: Luteinizing hormone; E2: Estradiol; FT: Free testosterone
Table III. Evaluation of pregnancy outcomes in study and control groups
Miscarriage abs. N and % Preterm labor Timely delivery
Groups
I trim II trim All Vaginaldelivery
Cesarean
delivery All
Study group 3 (3.12%) - 3 (3.12%) - 82 (85.42%) 11 (11.46%) 93 (96.88%)
Control group 14 (17.95%) - 14 (17.95%) 3 (3.85%) 54 (69.23%) 7 (8.97%) 61 (78.20%)
𝜒 2 10.73 10.73 3.76 6.61 0.29 14.745
p 0.002 0.002 0.053 0.011 0.593 <0.001
Data presented as n (%); categorical variables were compared using the Pearson’s 𝜒2
4. Discussion
PRL is known to directly affect the ovaries. It
inhibits secretion of estrogen and progesterone.
Hyperprolactinemia causes inhibition of
luteinization and steroidogenesis in the ovaries
(15-17). In our study, patients had a moderate
increase in PRL at initial stage. The higher the
PRL level, the greater the decrease in E2 and
progesterone levels in the blood serum, FSH
and LH levels remained within the norm. On
the background of moderate hyperprolactinemia
73.96% of women included in our study had
oligomenorrhea, 4.17% had oligomenorrhea,
14.58% secondary amenorrhea, and 7.29% regular
menstrual cycle, of which 71.43% had anovulation
and 28.57% luteal phase deficiency. It should be
mentioned that at higher PRL levels more profound
menstrual disorders were observed. In the study
reported by other authors, the rate of amenorrhea
was 35% (17), which is probably due to the higher
PRL levels compared to our study.
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The study of the prevalence of
hyperprolactinemia among young women
with menstrual disorders showed that
hyperprolactinemia was a relatively common
cause of secondary amenorrhea and equaled
to 13.8% (18); our treatment significantly
reduced and normalized PRL levels. As a
result, E2 and progesterone levels were
significantly elevated to normal, reflected
in the regulation of the menstrual cycle and
restoring of ovulation. In our study, continuous
treatment with dopamine agonist in women
with idiopathic hyperprolactinemia led to
the PRL level normalization, menstrual cycle
regulation, and occurrence of pregnancy in all
cases. According to C. Weil, in patients with
idiopathic hyperprolactinemia after treatment
with bromocriptine, in 80% PRL levels are
normalized, and in the absence of other
causes of infertility, pregnancy occurs in
60-80% (2). In our study, high effectiveness
of treatment is likely to be explained by its
duration: after the normalization of PRL levels,
women continued to receive bromocriptine
at maintenance doses until the occurrence of
pregnancy.
Crosignani indicates that treatment of
hyperprolactinemia should be long-term and
last for at least one year, as restoration of
ovulatory cycles takes time and at administration
of dopamine agonists pregnancy usually
occurs after six months (2). As generally
known, abnormal increase of PRL levels in
the blood cause menstrual cycle disorders,
anovulation, luteal phase deficiency, infertility,
RPL, worsening the pregnancy outcomes (6-
8, 19). According to our study, the timing of
normalization of blood PRL levels in women
with idiopathic hyperprolactinemia almost
coincides with the timing of menstrual cycle
regulation (two-five months) and ovulation is
restored later (three-seven months). According
to Majumdar and Sharma, in cases of idiopathic
hyperprolactinemia, lowering of PRL levels with
continuous treatment with bromocriptine begins
earlier, regulation of menstruation and restoration
of ovulation occur later and almost coincide with
each other. In addition, these durations are less
(PRL level start to decrease within first week,
and menstruation is regulated and ovulation
restored within about one-two months) (4),
than that observed in our study. According to
the results of our study, prolonged continuous
treatment with bromocriptine for three months
before and after ovulation was restored on
the background of barrier contraception, and
afterward till the pregnancy, also inclusion of
dydrogesterone in the treatment for support of
luteal phase after ovulations was restored for at
least three menstrual cycles before and in the first
trimester of pregnancy, significantly improved
pregnancy outcomes. Such complications
of pregnancy as threatened preterm labor,
placental insufficiency, and preeclampsia were
low.
According to Hirahara et al, continuous
treatment with bromocriptine until the ninth
week of pregnancy of women with idiopathic
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hyperprolactinemia with the history of RPL
significantly reduces the number of spontaneous
abortions (13). According to some authors,
a secondary luteal deficiency may occur
during pathological hyperprolactinemia
due to pituitary dysfunction (2, 3, 7, 8).
Conditions related to inadequate secretion
of progesterone corpus luteum may affect
pregnancy outcomes, as sufficient amount
of progesterone is essential for secretory
transformation of endometrium and normal
embryo implantation and growth (6, 8). In
our study, before treatment, progesterone
level was decreased in women with idiopathic
hyperprolactinemia, and after normalization of
PRL level, there was a significant increase in its
level. Pregnancy loss occurred in three cases.
In all other cases, pregnancy resulted in a live
healthy newborn. According to Carp, treatment
with dydrogesterone (generally progesterone)
is somewhat empirical, however, results of
systematic review has shown that its use reduces
the likelihood of spontaneous abortions by 47%
compared to standard managed pregnancies,
and overall, it reduces the absolute rate of
pregnancy losses by 11% (20). An administration
of dydrogesterone also lowers the rate of
subsequent pregnancy loss in women with
RPL (21). According to other authors also, an
administration of oral dydrogesterone improves
pregnancy outcomes in women with RPL (22-
24). However, there is no data in the literature
on how dydrogesterone administration before
and during pregnancy improves pregnancy
outcomes in women with hyperprolactinemia.
If we take into account the consideration,
that hyperprolactinemia is characterized by
secondary luteal insufficiency, it becomes clear
how important it is to treat with dydrogesterone
in support of the luteal phase in women with
hyperprolactinemia.
5. Conclusion
Prolonged and continuous treatment with
bromocriptine before the pregnancy and with
dydrogesterone before and in the first trimester
of the pregnancy led to a significantly high
rate of timely delivery in the study group
compared to the control group. The rate of
miscarriage and preterm labor was significantly
low in the study group than in the control
group. In both the groups miscarriages were
reported in the first trimester of the pregnancy.
Pregnancy outcomes in women with idiopathic
hyperprolactinemia were improved by prolonged
and continuous treatment with bromocriptine
before the occurrence of pregnancy and use
of dydrogesterone to support the luteal phase
before pregnancy and during the first trimester of
pregnancy.
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